dc.contributor.author | Ma, TM | |
dc.contributor.author | Chu, F-I | |
dc.contributor.author | Sandler, H | |
dc.contributor.author | Feng, FY | |
dc.contributor.author | Efstathiou, JA | |
dc.contributor.author | Jones, CU | |
dc.contributor.author | Roach, M | |
dc.contributor.author | Rosenthal, SA | |
dc.contributor.author | Pisansky, T | |
dc.contributor.author | Michalski, JM | |
dc.contributor.author | Bolla, M | |
dc.contributor.author | de Reijke, TM | |
dc.contributor.author | Maingon, P | |
dc.contributor.author | Neven, A | |
dc.contributor.author | Denham, J | |
dc.contributor.author | Steigler, A | |
dc.contributor.author | Joseph, D | |
dc.contributor.author | Nabid, A | |
dc.contributor.author | Souhami, L | |
dc.contributor.author | Carrier, N | |
dc.contributor.author | Incrocci, L | |
dc.contributor.author | Heemsbergen, W | |
dc.contributor.author | Pos, FJ | |
dc.contributor.author | Sydes, MR | |
dc.contributor.author | Dearnaley, DP | |
dc.contributor.author | Tree, AC | |
dc.contributor.author | Syndikus, I | |
dc.contributor.author | Hall, E | |
dc.contributor.author | Cruickshank, C | |
dc.contributor.author | Malone, S | |
dc.contributor.author | Roy, S | |
dc.contributor.author | Sun, Y | |
dc.contributor.author | Zaorsky, NG | |
dc.contributor.author | Nickols, NG | |
dc.contributor.author | Reiter, RE | |
dc.contributor.author | Rettig, MB | |
dc.contributor.author | Steinberg, ML | |
dc.contributor.author | Reddy, VK | |
dc.contributor.author | Xiang, M | |
dc.contributor.author | Romero, T | |
dc.contributor.author | Spratt, DE | |
dc.contributor.author | Kishan, AU | |
dc.contributor.author | Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2022-10-18T10:22:48Z | |
dc.date.available | 2022-10-18T10:22:48Z | |
dc.date.issued | 2022-08-04 | |
dc.identifier | S0302-2838(22)02523-4 | |
dc.identifier.citation | European Urology, 2022, 82 (5), pp. S0302-2838(22)02523-4 - | en_US |
dc.identifier.issn | 0302-2838 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5546 | |
dc.identifier.eissn | 1873-7560 | |
dc.identifier.eissn | 1873-7560 | |
dc.identifier.doi | 10.1016/j.eururo.2022.07.011 | |
dc.identifier.doi | 10.1016/j.eururo.2022.07.011 | |
dc.description.abstract | CONTEXT: The prognostic importance of local failure after definitive radiotherapy (RT) in National Comprehensive Cancer Network intermediate- and high-risk prostate cancer (PCa) patients remains unclear. OBJECTIVE: To evaluate the prognostic impact of local failure and the kinetics of distant metastasis following RT. EVIDENCE ACQUISITION: A pooled analysis was performed on individual patient data of 12 533 PCa (6288 high-risk and 6245 intermediate-risk) patients enrolled in 18 randomized trials (conducted between 1985 and 2015) within the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium. Multivariable Cox proportional hazard (PH) models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), distant metastasis-free survival (DMFS), and local failure as a time-dependent covariate. Markov PH models were developed to evaluate the impact of specific transition states. EVIDENCE SYNTHESIS: The median follow-up was 11 yr. There were 795 (13%) local failure events and 1288 (21%) distant metastases for high-risk patients and 449 (7.2%) and 451 (7.2%) for intermediate-risk patients, respectively. For both groups, 81% of distant metastases developed from a clinically relapse-free state (cRF state). Local failure was significantly associated with OS (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.06-1.30), PCSS (HR 2.02, 95% CI 1.75-2.33), and DMFS (HR 1.94, 95% CI 1.75-2.15, p < 0.01 for all) in high-risk patients. Local failure was also significantly associated with DMFS (HR 1.57, 95% CI 1.36-1.81) but not with OS in intermediate-risk patients. Patients without local failure had a significantly lower HR of transitioning to a PCa-specific death state than those who had local failure (HR 0.32, 95% CI 0.21-0.50, p < 0.001). At later time points, more distant metastases emerged after a local failure event for both groups. CONCLUSIONS: Local failure is an independent prognosticator of OS, PCSS, and DMFS in high-risk and of DMFS in intermediate-risk PCa. Distant metastasis predominantly developed from the cRF state, underscoring the importance of addressing occult microscopic disease. However a "second wave" of distant metastases occurs subsequent to local failure events, and optimization of local control may reduce the risk of distant metastasis. PATIENT SUMMARY: Among men receiving definitive radiation therapy for high- and intermediate-risk prostate cancer, about 10% experience local recurrence, and they are at significantly increased risks of further disease progression. About 80% of patients who develop distant metastasis do not have a detectable local recurrence preceding it. | |
dc.format | Print-Electronic | |
dc.format.extent | S0302-2838(22)02523-4 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier BV | en_US |
dc.relation.ispartof | European Urology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Distant metastasis | |
dc.subject | Local control | |
dc.subject | Local failure | |
dc.subject | Pooled analysis | |
dc.subject | Prostate cancer | |
dc.subject | Radiation therapy | |
dc.title | Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-07-14 | |
dc.date.updated | 2022-10-18T10:12:21Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.eururo.2022.07.011 | en_US |
rioxxterms.licenseref.startdate | 2022-08-04 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35934601 | |
pubs.issue | 5 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.eururo.2022.07.011 | |
pubs.volume | 82 | |
icr.researchteam | Clinic Acad RT Dearnaley | en_US |
icr.researchteam | Clin Trials & Stats Unit | en_US |
dc.contributor.icrauthor | Dearnaley, David | |
dc.contributor.icrauthor | Cruickshank, Clare | |
icr.provenance | Deposited by Mr Arek Surman on 2022-10-18. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0302283822025234-main.pdf | |